REN and COVID-19: Currently, following on at least three randomized clinical trials, there is no evidence that discontinuing renin-angiotensin system inhibitors for underlying medical conditions offers a clinical benefit for patients with COVID-19 (Bauer et al., 2021; Lopes et al., 2021b; Cohen et al., 2021).